Recent studies with a combination of INCB024360 and the PD-1 blockade (pembrolizumab) in patients with advanced melanoma did not show any significant improvement compared with the single PD-1 blockade, which supports the clinical relevance of our studies and indicates that IDO1 inhibition alone will not enhance the effect of immune checkpoint blockade7,36. Here, PDCD1 is linked to melanoma.